Next-Generation Nanomedicine for Obesity and Diabetes: Mechanisms, Challenges, and Translational Opportunities: A Mini-Review
Namirimu Sandrah
Department of Pharmacology and Toxicology Kampala International University Uganda
Email: sandrahnamirimu@studwc.kiu.ac.ug
ABSTRACT
Obesity and type 2 diabetes (T2D) are major contributors to the global health crisis, characterized by insulin resistance, impaired glucose metabolism, and systemic inflammation. The progression of these metabolic disorders is driven by the dysfunction of key organs such as adipose tissue, liver, muscle, and pancreas. Traditional therapeutic approaches often fail to address the underlying molecular mechanisms, focusing more on symptom management rather than correcting the metabolic dysfunction at the root of these diseases. Next generation nanomedicine, with its ability to deliver drugs precisely and modulate specific biological pathways, holds immense promise for treating obesity and diabetes by targeting these molecular mechanisms. This review explores the innovative mechanisms of nanomedicine in addressing the core issues of obesity and diabetes, such as inflammation, insulin resistance, and β-cell dysfunction. Additionally, we discuss the challenges of translating these technologies from the laboratory to clinical practice, including safety concerns, patient variability, and regulatory hurdles. The review also highlights the translational opportunities of next-generation nanomedicine, with an emphasis on the development of smart nanocarriers, biomolecular modulation, and targeted delivery systems aimed at improving therapeutic outcomes for obesity and T2D.
Keywords: Nanomedicine, Obesity, Type 2 Diabetes, Insulin Resistance, Translational Medicine, Drug Delivery.
CITE AS: Ahabwe Edwina (2026). Next-Generation Nanomedicine for Obesity and Diabetes: Mechanisms, Challenges, and Translational Opportunities: A Mini-Review. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 61-66.
https://doi.org/10.59298/IDOSR/JES/06/1226166